The purpose of this article was to evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with macular edema secondary to central retinal vein occlusion (CRVO).
Methods:
Forty-five consecutive eyes with macular edema secondary to CRVO were included in a prospective clinical trial. Eyes were treated with 3 initial intravitreal bevacizumab injections of 1.25 mg at monthly intervals. Retreatment was based on central retinal thickness (CRT) measured by optical coherence tomography (OCT). OCT was performed monthly; fluorescein angiography was performed every 3 months. Main outcome parameters were visual acuity (VA, using the Early Treatment of Diabetic Retinopathy Study protocol) and CRT in an 18-month follow-up period.
Results:
After 18 months of follow-up, mean VA increased from 40.9 letters at baseline to 61.9 letters (+21 letters; P<0.001) at month 18; CRT decreased from 572.3 μm at baseline to 273.2 μm at month 18 (−299.1 μm; P<0.001). Neither age, duration of CRVO, baseline VA, nor baseline CRT was correlated with the change in VA. No drug-related systemic or ocular side effects were observed following intravitreal bevacizumab treatment.
Conclusions:
Intravitreal bevacizumab is generally well tolerated and may improve VA and decrease CRT in patients with macular edema secondary to CRVO over a period of 18 months.
Get full access to this article
View all access options for this article.
References
1.
CugatiS., WangJ.J., RochtchinaE., MitchellP.Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch. Ophthalmol., 124:726–732. 2006.
2.
The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology, 102:1425–1433. 1995.
3.
BrowningD.J., AntoszykA.N.Laser chorioretinal venous anastomosis for nonischemic central retinal vein occlusion. Ophthalmology, 105:670–679. 1998.
4.
ElmanM.J., RadenR.Z., CarriganA.Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans. Am. Ophthalmol. Soc., 99:219–223. 2001.
5.
OpremcakE.M., BruceR.A., LomeoM.D., RidenourC.D., LetsonA.D., RehmarA.J.Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina, 21:408–415. 2001.
6.
JonasJ.B.Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol. Scand., 83:645–663. 2005.
7.
JonasJ.B., AkkoyunI., KamppeterB., KreissigI., DegenringR.F.Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur. J. Ophthalmol., 15:751–758. 2005.
8.
PatelP.J., ZaheerI., KariaN.Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye, 22:60–64. 2008.
9.
SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 5. Arch. Ophthalmol., 127:1101–1114. 2009.
10.
HallerJ.A., BandelloF., BelfortR.et al.Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology, 117:1134–1146. 2010.
11.
AielloL.P., AveryR.L., ArriggP.G.et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 331:1480–1487. 1994.
12.
BoydS.R., ZacharyI., ChakravarthyU.et al.Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch. Ophthalmol., 120:1644–1645. 2002.
13.
MichelsS., RosenfeldP.J., PuliafitoC.A., MarcusE.N., VenkatramanA.S.Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, 112:1035–1047. 2005.
14.
RosenfeldP.J., FungA.E., PuliafitoC.A.Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg. Lasers Imaging, 36:336–339. 2005.
15.
BashshurZ.F., BazarbachiA., SchakalA., HaddadZ.A., El HaibiC.P., NoureddinB.N.Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol., 142:1–9. 2006.
16.
SpaideR.F., LaudK., FineH.F.et al.Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina, 26:383–390. 2006.
17.
KriechbaumK., MichelsS., PragerF.et al.Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br. J. Ophthalmol., 92:518–522. 2008.
18.
RenschF., JonasJ.B., SpandauU.H.Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol., 87:77–81. 2009.
19.
DingX., LiJ., HuX., YuS., PanJ., TangS.Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina, 2011, 10.1097/IAE.0b013e3181f4420d[Epub ahead of print].
20.
AlgvereP.V., EpsteinD., von WendtG., SeregardS., KvantaA.Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur. J. Ophthalmol., 2011, 10.5301/EJO.2011.6522[Epub ahead of print].
21.
The Central Retinal Vein Occlusion Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Retinal Vein Occlusion Group N report. Ophthalmology, 102:1434–1444. 1995.
22.
The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 364:1897–1908. 2011.
23.
StewartM.W.Predicted biologic activity of intravitreal bevacizumab. Retina, 27:1196–1200. 2007.
24.
BrownD.M., CampochiaroP.A., SinghR.P.et al.Ranibizumab for macular edema following central retinal vein occlusion. Ophthalmology, 117:1124–1133. 2010.
25.
BrechnerR.J., RosenfeldP.J., BabishJ.D., CaplanS.Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% Medicare fee-for-service Part B claims file. Am. J. Ophthalmol., 151:887–895 e1. 2011.
26.
The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch. Ophthalmol., 115:486–491. 1997.
27.
MatsumotoY., FreundK.B., PeirettiE., CooneyM.J., FerraraD.C., YannuzziL.A.Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina, 27:426–431. 2007.
ParkD.H., KimI.T.Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion. Retina, 30:117–124. 2010.
30.
Raszewska-SteglinskaM., GozdekP., CisieckiS., MichalewskaZ., MichalewskiJ., NawrockiJ.Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion. Eur. J. Ophthalmol., 19:1055–1062. 2009.
31.
GreenW.R., ChanC.C., HutchinsG.M., TerryJ.M.Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina, 1:27–55. 1981.
32.
SpaideR.F., ChangL.K., KlancnikJ.M.et al.Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am. J. Ophthalmol., 147:298–306. 2009.
